期刊
KIDNEY INTERNATIONAL
卷 97, 期 4, 页码 655-656出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2019.12.020
关键词
-
资金
- Australian National Health and Medical Research Council CJ Martin Overseas Biomedical Early Career Fellowship
A dose escalation study of adipose-derived human mesenchymal stem cell (MSC) therapy was studied in 21 subjects. This dose escalation study confirmed no significant cellular toxicity, but it showed improvement in renal oxygenation and glomerular filtration rate. No significant renal toxicity from cell therapy was shown. A reduction in inflammatory markers including tumor necrosis factor-a, interferon-g, and neutrophil gelatinase-associated lipocalin was noted in subjects receiving MSC therapy. This study provides short-term safety and renal efficacy for MSC therapy and paves the way forward for future MSC-based interventions in renovascular disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据